MANKIND — Mankind Pharma Share Price
Last trade - 00:00- IN₹1.01tn
- IN₹1.07tn
- IN₹122.07bn
- 70
- 10
- 77
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 44.06 | ||
| PEG Ratio (f) | 4.32 | ||
| EPS Growth (f) | 11.36% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.02 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 51.89 | ||
| Price to Sales | 8.25 | ||
| EV to EBITDA | 35.41 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.85% | ||
| Return on Equity | 16.77% | ||
| Operating Margin | 19.63% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 62,144.31 | 77,815.55 | 87,494.33 | 102,604.4 | 122,074.4 | 148,273.71 | 166,435.08 | 15.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +17.29 | +10.57 | -9.34 | +48.63 | +3.01 | +4.92 | +28.55 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
Directors
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- July 3rd, 1991
- Public Since
- May 9th, 2023
- No. of Employees
- 19,540
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 412,671,039
- Address
- 262, Okhla Industrial Estate, Phase-III, NEW DELHI, 110020
- Web
- https://www.mankindpharma.com/
- Phone
- +91 1147476600
- Auditors
- S.R. Batliboi & Co. LLP
Upcoming Events for MANKIND
Similar to MANKIND
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 12:53 UTC, shares in Mankind Pharma are trading at IN₹2,439.50. This share price information is delayed by 15 minutes.
Shares in Mankind Pharma last closed at IN₹2,439.50 and the price had moved by +12.26% over the past 365 days. In terms of relative price strength the Mankind Pharma share price has outperformed the S&P BSE 100 Index by +8.26% over the past year.
The overall consensus recommendation for Mankind Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMankind Pharma does not currently pay a dividend.
Mankind Pharma does not currently pay a dividend.
Mankind Pharma does not currently pay a dividend.
To buy shares in Mankind Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹2,439.50, shares in Mankind Pharma had a market capitalisation of IN₹1.01tn.
Here are the trading details for Mankind Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: MANKIND
Based on an overall assessment of its quality, value and momentum Mankind Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mankind Pharma is IN₹2,694.73. That is 10.46% above the last closing price of IN₹2,439.50.
Analysts covering Mankind Pharma currently have a consensus Earnings Per Share (EPS) forecast of IN₹51.50 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mankind Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -22.28%.
As of the last closing price of IN₹2,439.50, shares in Mankind Pharma were trading -3.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mankind Pharma PE ratio based on its reported earnings over the past 12 months is 44.06. The shares last closed at IN₹2,439.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Mankind Pharma's directors